肥厚型心肌病和假肥大型肌营养不良症家系的致病基因及临床研究
|
摘要
研究背景
肥厚型心肌病(hypertrophic cardiomyopathy, HCM)是由于单基因突变而导致的常染色体显性遗传性疾病,主要表现为左心室和(或)右心室及室间隔不对称肥厚、心室腔变小、心室顺应性降低。是青少年和运动员心源性猝死(Sudden cardiac death,SCD)最常见原因,可在任何年龄段发病,有显著的家族聚集性,家族性发病者占全部病例的50%,年死亡率约为1%-2%,具有发病年龄、发病程度和猝死风险等临床表型多样性的特点。研究发现：相关突变基因主要定位在β肌球蛋白重链基因、肌球蛋白结合蛋白C基因、心脏肌钙蛋白T基因等肌小节蛋白基因以及相关的线粒体基因与修饰基因上,超过900种不同的基因突变类型与HCM发生发展以及临床表型有关。目前在已经明确导致HCM的基因中发现至少1400个突变位点。指南中8个明确导致HCM的基因为p肌球蛋白重链(MYH7)、肌球蛋白结合蛋白c(MYBPC3)、肌钙蛋白T(TNNT2)、肌钙蛋白I(TNNI3)、a肌球蛋白(TPM1)、肌动蛋白(ACTC)、调节轻链(MYL2)和基本轻链基因(MYL3)。其中p肌球蛋白重链基因(MYH7)、肌球蛋白结合蛋白C基因(MYBPC3)及心脏肌钙蛋白T基因(TNT)是最常见的3个HCM致病基因,由这些基因突变引起的HCM约占75%。
传统的Sanger法测序是遗传病分子诊断的金标准,但是将已知候选基因进行逐一排查耗时、费力及价格昂贵,特别是HCM基因比较多而且复杂。第二代高通量基因测序(Next generation squencing, NGS)以高通量、速度快、低成本为主要特征,可直接通过聚合酶或连接酶进行体外测序合成。运用NGS方法,不仅能检测到遗传性疾病的致病基因突变,而且能够发现新的基因或突变,全面地勾勒出基因组上的变异图谱。
研究目的
对家族性肥厚型心肌病患者进行第二代测序和家系验证,来分析家族性肥厚型心肌病患者的的致病基因及突变位点,分析基因型与临床表型及预后的关系。
研究方法
应用二代测序方法对家族性肥厚型心肌病家系的先证者进行基因检测,根据测序结果设计目标基因片段的引物,对患者及其家系成员进行第一代Sanger测序,即聚合酶链式反应扩增其功能区外显子片断,双脱氧末端终止法测序。分析该家系中所有患者的临床表型特点,并对其进行临床随访。
研究结果
1个肥厚型心肌病家系的先证者经第二代测序检测发现MYH7基因的18号外显子上c.1987G>A突变,导致精氨酸变为半胱氨酸,即Arg663Cys (R663C)。对其家系中其他成员进行基因筛查,全部进行p肌球蛋白重链(MYH7)18号外显子的目的基因片段的筛查,其中有4个家系成员同时有Arg663Cys突变,而正常对照组在同一位置未见异常。该家系患者临床表现为活动后胸闷伴晕厥或猝死,呈恶性表现,先证者进行了改良的Morrow外科手术,术后症状消失,临床随访2年,患者恢复良好,无活动后胸闷胸痛不适,超声心动图未发现进展性改变。
另外1个肥厚型心肌病家系的先证者经第二代测序检测发现MYBPC3基因的14号外显子上新的移码突变c.1374delC,移码在465号氨基酸终止,终止密码(TGA),即p.Arg458ArgfsX8(p.R458Rfs),该突变为世界上首次报道。对其家系中其他成员进行Sanger测序,其中有3个家系成员同时有p.R458Rfs突变,而正常对照组在同一位置未见异常。该家系患者临床表现和预后有异质性,先证者及其弟弟表现为活动后胸闷,先证者的母亲和小姨已猝死,而其妹妹和女儿仅为突变携带者,无临床表现。
结论
p肌球蛋白重链基因的18号外显子突变Arg663Cys是家系1的致病突变。Arg663Cys所致肥厚型心肌病的临床症状出现早,多合并左室流出道的梗阻,容易出现晕厥、猝死等不良事件,预后较差,但是积极地进行手术治疗可缓解症状并能改善预后。
家系2的致病突变是MYBPC3基因的14号外显子上新的移码突变c.1374delC突变,p.R458Rfs,该突变为世界上首次报道,该突变的表型有异质性,预后不同。
研究背景
肥厚型心肌病是一种以左室非对称性肥厚为特征的原发性心肌病,其主要并发症有心房血栓、心律失常、心衰和猝死,但合并左室血栓的肥厚型心肌病临床报道较少,本研究分析阜外心血管病医院10年间有左室血栓的肥厚型心肌病患者的临床资料,并探讨其临床特征、治疗及预后情况,为临床工作提供参考。
研究目的
探讨经心脏核磁证实合并有左心室血栓的肥厚型心肌病(Hypertrophic cardiomyopathy, HCM)患者的临床特征和预后情况。
研究方法
回顾性分析阜外心血管病医院2002年1月～2012年12月住院病人中经心脏核磁共振(cardiac magnetic resonance, CMR)证实有左室血栓的HCM患者的临床资料,并进行临床随访。
研究结果
经心脏核磁证实有左室血栓的HCM患者共6例(血栓组),无左室血栓的HCM患者共284例(无血栓组),血栓组的家族史比例、室性心律失常、左房内径、左室内径和室壁瘤明显高于无血栓组(p<0.05),而左室射血分数和流出道梗阻比例明显低于无血栓组(p<0.05)。有左室血栓的患者接受华法令抗凝治疗,随访17～59月,未发现血栓栓塞,2例复查血栓消失,3例死亡,1例进行了全心脏移植。
结论
肥厚型心肌病合并左室血栓见于有室壁瘤或左室射血分数低下的患者,多合并室性心律失常,预后差；可发生栓塞事件,华法令可有效治疗左室血栓。
背景：
假肥大型肌营养不良症是由抗肌萎缩蛋白基因突变所致的一种X连锁隐性遗传神经肌肉疾病,又称为杜氏或贝克肌营养不良(Duchenne's or Becker's muscular dystrophy, DMD or BMD),是以缓慢进行性加重的对称性肌无力和肌萎缩为特点的遗传性肌肉病变,其中DMD病情严重,预后差；BMD病情进展相对缓慢,可累及心脏。
目的：
总结假肥大型肌营养不良症伴心脏扩大患者家系的临床特征并进行基因诊断、分析和治疗及预后,为临床诊治提供借鉴。
方法：
对假肥大型肌营养不良症伴心脏扩大的先证者和家系成员进行血清肌酶、肌电图、心电图、心脏彩色超声检查及心脏核磁等临床检查,并采用Sanger直接测序的方法进行抗肌萎缩蛋白基因突变的检测,同时对100例无血缘关系的健康人群进行该位点的基因扩增测序,以排除所发现的突变为未知人群多态位点的可能。对确诊患者根据病情进行对症治疗并对其进行随访。
结果：
先证者符合BMD诊断,基因检测结果提示先证者携带dystrophin基因突变(c.4998_5000Del GCA,p.1667delAla,为首次报道)。家系成员中检测出3例患者携带以上突变,携带者均表现为四肢近端肌肉萎缩、无力,双侧腓肠肌假性肥大,血清肌酶的水平显著增高,心脏均受累,先证者表现为晚期心衰,并进行心脏移植手术,后恢复良好。
结论：
基因检测可为假肥大型肌营养不良症先证者及其家系成员进行明确诊断；对于假肥大型肌营养不良症伴心脏扩大引起心力衰竭的患者进行心脏移植术是治疗晚期患者可行有效的方法。
Background
Hypertrophic cardiomyopathy (HCM) is an autosomal-dominant monogenic form of cardiac disease caused by a mutation in one of the genes that encode a protein from the sarcomere, Z-disc, or intracellular calcium modulator and is characterized by unexplained left ventricular hypertrophy. It shows high variability in genetic heterogeneity and phenotypic characteristics. The genetic etiology responsible for HCM in many individuals remains unclear. Many causative genes have already been identified, including β-tropomyosin or myosin heavy chain7(MYH7gene), cardiac myosin binding protein C (MYBPC3gene), cardiac troponin T type2(TNNT2gene), cardiac troponin I type3(TNNI3gene), myosin light chain3(MYL3gene), myosin light chain2regulatory (MYL2gene), cardiac a-actin (ACTC gene) and, titin (TTN gene) and etc.
Sanger sequencing is the traditional gold standard in the molecule diagnosis of genetic disease, but time-consuming, laborious and expensive to each investigate for the known candidate genes, especially in HCM. Next generation sequencing technology, with features of high through put, rapid sequencing and low cost, brings revolutionary changes in the fields of detecting gene mutations. The process of using this method to dectect mutations is simple. Researchers can combine whole genomere sequencing, target sequencing and transcriptome sequencing to dectect mutations in all-around, high accurate way.
Objective
Our aims are to identify the disease-causing gene mutation with familial hypertrophic cardiomyopathy (FHCM) by next generation sequencing, and to analyze the correlation between their genotype and phenotype, prognosis.
Methods
We choose two Chinese pedigrees with HCM and extracted their DNA from whole blood. According to each of the21established HCM genes, the exons in the functional regions of the genes with mutation were amplified with PCR by targeted next-generation DNA sequencing. Proband were sequenced with the next generation DNA sequencing method. According to the results of sequencing, the probands were followed by Sanger sequencing, and the exon in the functional regions of the gene were amplified with PCR and the products were sequenced for their family members. The relation between the genotype and phenotype was analyzed in these families, and the products were directly sequenced.100normal subjects were recruited as control.
Results
One missence mutation c.1987G>A (Arg663Cys) was identified in exon18of the beta myosin heavy chain gene in one family hypertrophic cardiomyopathy by next generation sequencing. Screening for of her family members by Sanger sequencing, and there are4family members also with mutation Arg663Cys in Exon18of the beta myosin heavy chain gene. The results of genetic test were normal in one hundred controls. The patients with mutation Arg663Cys clinically showed chest pain early, syncope, or sudden cardiac death. After undergoing Morrow operation, the proband had recovered well, and in the follow-up period for two years, she never feels chest pain and syncope.
A novel frame shift mutation c.1374delC (p.R458Rfs) was identified in exon14of the cardiac myosin binding protein C gene in pedigree2. Screening for of her family members by Sanger sequencing, and there are3family members also with mutation R458Rfs in Exon14of MYBPC3gene. The results of genetic test were normal in one hundred controls. However, the members of the same HCM family with the R458Rfs mutation showed differences in phenotype and prognosis.
Conclusions
The mutation Arg663Cys in Exon18of beta myosin heavy chain gene is the disease-causing gene in family1by next generation sequencing. The symptoms of patients occur early associated with left ventricular outflow tract obstruction and show chest pain, syncope and sudden death. Their prognosis seems poor in this pedigree of HCM. However, Morrow operation treatment can relieve symptoms and improve prognosis if the patients can actively carry out surgery.
A novel frame shift mutation c.1374delC (p.R458Rfs) was identified in exon14of the cardiac myosin binding protein C gene in pedigree2. The patients with this mutation clinically showed differences in phenotype and prognosis. The heterogeneity suggested that multiple factors may be involved in the pathogenesis of HCM.
Objective:
We aimed to retrospectively analyze the clinical features and prognosis of Hypertrophic cardiomyopathy patients with left ventricular thrombus.
Methods:
We retrospectively analyzed the data of HCM patients with left ventricular thrombus diagnosed by CMR in FuWai Hospital from January2002to December2012, and followed-up their survival states.
Results:
Left ventricular thrombosis was confirmed by MRI in6cases of HCM (thrombosis group), and no left ventricular thrombosis in284cases of HCM (no thrombus group), the ratio of family history of thrombosis group, ventricular arrhythmia, left atrial diameter, left ventricular diameter and ventricular aneurysm were significantly higher than those without thrombosis group (p<0.05), and left ventricular ejection fraction and outflow tract obstruction was significantly lower than no thrombus group (p<0.05).All patients received anticoagulation therapy with warfarin. During follow up (17-59) months, no thromboembolic events was recorded, and thrombus disappear in2patients.3cases died of heart failure and SCD. One patient received heart transplantation.
Conclusion:
Left ventricular thrombosis was seen in Hypertrophic cardiomyopathy patients with left ventricular aneurysm and lower left ventricular ejection fraction. Ventricular arrhythmia and poor prognosis were found in the majority of patients. Although embolic events occurred because of the left ventricular thrombus, warfarin can cure them.
Background:
Duchenne's or Becker's muscular dystrophy is a serious X-linked neuromuscular disorder. Mutations in the dystrophin gene on chromosome Xp21.1. have been reported to cause BMD. It primarily involved the skeletal muscle, characterized by weakness and muscle atrophy of hereditary muscle disease following as low progressive increase of symmetry. DMD is usually with serious condition and with a poor prognosis. BMD patients can usually walk and have a near normal life span, and there is a chance of them developing cardiac problems.
Objective:
To study the clinical characteristics and genetic analysis and management of Becker's muscular dystrophy combined with cardiac involvement, and to expand our understanding of this disorder.
Methods:
The proband and the family members had genetic testing, and these subjects also had physical examination and received muscle biopsy and routine pathological checks and cardiac evaluation. One hundred control subjects without diagnostic features of BMD were also recruited. Genomic DNA was extracted from leukocytes of peripheral blood from the patients and the control subjects. We screened the dystrophin gene in the indexes, and also screened for the mutation in their families and100controls.
Results:
The proband was diagnosed with BMD by the identification of a mutation (c.4998_5000Del GCA, p.1667delAla) in the exon35of the dystrophin gene. Three cases were diagnosed with BMD by the identification of this mutation. All genetically affected subjects had a history of weakness of the quadriceps femoris as well as increased serum creatine kinase level at rest and cardiac involvement. After heart transplantation, the proband recovered well.
Conclusion:
Genetic analysis enables a precise diagnosis of BMD, and heart transplantation is an effective treatment for the patient with severe heart failure.
肥厚型心肌病(hypertrophic cardiomyopathy, HCM)是由于单基因突变而导致的常染色体显性遗传性疾病,主要表现为左心室和(或)右心室及室间隔不对称肥厚、心室腔变小、心室顺应性降低。是青少年和运动员心源性猝死(Sudden cardiac death,SCD)最常见原因,可在任何年龄段发病,有显著的家族聚集性,家族性发病者占全部病例的50%,年死亡率约为1%-2%,具有发病年龄、发病程度和猝死风险等临床表型多样性的特点。研究发现：相关突变基因主要定位在β肌球蛋白重链基因、肌球蛋白结合蛋白C基因、心脏肌钙蛋白T基因等肌小节蛋白基因以及相关的线粒体基因与修饰基因上,超过900种不同的基因突变类型与HCM发生发展以及临床表型有关。目前在已经明确导致HCM的基因中发现至少1400个突变位点。指南中8个明确导致HCM的基因为p肌球蛋白重链(MYH7)、肌球蛋白结合蛋白c(MYBPC3)、肌钙蛋白T(TNNT2)、肌钙蛋白I(TNNI3)、a肌球蛋白(TPM1)、肌动蛋白(ACTC)、调节轻链(MYL2)和基本轻链基因(MYL3)。其中p肌球蛋白重链基因(MYH7)、肌球蛋白结合蛋白C基因(MYBPC3)及心脏肌钙蛋白T基因(TNT)是最常见的3个HCM致病基因,由这些基因突变引起的HCM约占75%。
传统的Sanger法测序是遗传病分子诊断的金标准,但是将已知候选基因进行逐一排查耗时、费力及价格昂贵,特别是HCM基因比较多而且复杂。第二代高通量基因测序(Next generation squencing, NGS)以高通量、速度快、低成本为主要特征,可直接通过聚合酶或连接酶进行体外测序合成。运用NGS方法,不仅能检测到遗传性疾病的致病基因突变,而且能够发现新的基因或突变,全面地勾勒出基因组上的变异图谱。
研究目的
对家族性肥厚型心肌病患者进行第二代测序和家系验证,来分析家族性肥厚型心肌病患者的的致病基因及突变位点,分析基因型与临床表型及预后的关系。
研究方法
应用二代测序方法对家族性肥厚型心肌病家系的先证者进行基因检测,根据测序结果设计目标基因片段的引物,对患者及其家系成员进行第一代Sanger测序,即聚合酶链式反应扩增其功能区外显子片断,双脱氧末端终止法测序。分析该家系中所有患者的临床表型特点,并对其进行临床随访。
研究结果
1个肥厚型心肌病家系的先证者经第二代测序检测发现MYH7基因的18号外显子上c.1987G>A突变,导致精氨酸变为半胱氨酸,即Arg663Cys (R663C)。对其家系中其他成员进行基因筛查,全部进行p肌球蛋白重链(MYH7)18号外显子的目的基因片段的筛查,其中有4个家系成员同时有Arg663Cys突变,而正常对照组在同一位置未见异常。该家系患者临床表现为活动后胸闷伴晕厥或猝死,呈恶性表现,先证者进行了改良的Morrow外科手术,术后症状消失,临床随访2年,患者恢复良好,无活动后胸闷胸痛不适,超声心动图未发现进展性改变。
另外1个肥厚型心肌病家系的先证者经第二代测序检测发现MYBPC3基因的14号外显子上新的移码突变c.1374delC,移码在465号氨基酸终止,终止密码(TGA),即p.Arg458ArgfsX8(p.R458Rfs),该突变为世界上首次报道。对其家系中其他成员进行Sanger测序,其中有3个家系成员同时有p.R458Rfs突变,而正常对照组在同一位置未见异常。该家系患者临床表现和预后有异质性,先证者及其弟弟表现为活动后胸闷,先证者的母亲和小姨已猝死,而其妹妹和女儿仅为突变携带者,无临床表现。
结论
p肌球蛋白重链基因的18号外显子突变Arg663Cys是家系1的致病突变。Arg663Cys所致肥厚型心肌病的临床症状出现早,多合并左室流出道的梗阻,容易出现晕厥、猝死等不良事件,预后较差,但是积极地进行手术治疗可缓解症状并能改善预后。
家系2的致病突变是MYBPC3基因的14号外显子上新的移码突变c.1374delC突变,p.R458Rfs,该突变为世界上首次报道,该突变的表型有异质性,预后不同。
研究背景
肥厚型心肌病是一种以左室非对称性肥厚为特征的原发性心肌病,其主要并发症有心房血栓、心律失常、心衰和猝死,但合并左室血栓的肥厚型心肌病临床报道较少,本研究分析阜外心血管病医院10年间有左室血栓的肥厚型心肌病患者的临床资料,并探讨其临床特征、治疗及预后情况,为临床工作提供参考。
研究目的
探讨经心脏核磁证实合并有左心室血栓的肥厚型心肌病(Hypertrophic cardiomyopathy, HCM)患者的临床特征和预后情况。
研究方法
回顾性分析阜外心血管病医院2002年1月～2012年12月住院病人中经心脏核磁共振(cardiac magnetic resonance, CMR)证实有左室血栓的HCM患者的临床资料,并进行临床随访。
研究结果
经心脏核磁证实有左室血栓的HCM患者共6例(血栓组),无左室血栓的HCM患者共284例(无血栓组),血栓组的家族史比例、室性心律失常、左房内径、左室内径和室壁瘤明显高于无血栓组(p<0.05),而左室射血分数和流出道梗阻比例明显低于无血栓组(p<0.05)。有左室血栓的患者接受华法令抗凝治疗,随访17～59月,未发现血栓栓塞,2例复查血栓消失,3例死亡,1例进行了全心脏移植。
结论
肥厚型心肌病合并左室血栓见于有室壁瘤或左室射血分数低下的患者,多合并室性心律失常,预后差；可发生栓塞事件,华法令可有效治疗左室血栓。
背景：
假肥大型肌营养不良症是由抗肌萎缩蛋白基因突变所致的一种X连锁隐性遗传神经肌肉疾病,又称为杜氏或贝克肌营养不良(Duchenne's or Becker's muscular dystrophy, DMD or BMD),是以缓慢进行性加重的对称性肌无力和肌萎缩为特点的遗传性肌肉病变,其中DMD病情严重,预后差；BMD病情进展相对缓慢,可累及心脏。
目的：
总结假肥大型肌营养不良症伴心脏扩大患者家系的临床特征并进行基因诊断、分析和治疗及预后,为临床诊治提供借鉴。
方法：
对假肥大型肌营养不良症伴心脏扩大的先证者和家系成员进行血清肌酶、肌电图、心电图、心脏彩色超声检查及心脏核磁等临床检查,并采用Sanger直接测序的方法进行抗肌萎缩蛋白基因突变的检测,同时对100例无血缘关系的健康人群进行该位点的基因扩增测序,以排除所发现的突变为未知人群多态位点的可能。对确诊患者根据病情进行对症治疗并对其进行随访。
结果：
先证者符合BMD诊断,基因检测结果提示先证者携带dystrophin基因突变(c.4998_5000Del GCA,p.1667delAla,为首次报道)。家系成员中检测出3例患者携带以上突变,携带者均表现为四肢近端肌肉萎缩、无力,双侧腓肠肌假性肥大,血清肌酶的水平显著增高,心脏均受累,先证者表现为晚期心衰,并进行心脏移植手术,后恢复良好。
结论：
基因检测可为假肥大型肌营养不良症先证者及其家系成员进行明确诊断；对于假肥大型肌营养不良症伴心脏扩大引起心力衰竭的患者进行心脏移植术是治疗晚期患者可行有效的方法。
Background
Hypertrophic cardiomyopathy (HCM) is an autosomal-dominant monogenic form of cardiac disease caused by a mutation in one of the genes that encode a protein from the sarcomere, Z-disc, or intracellular calcium modulator and is characterized by unexplained left ventricular hypertrophy. It shows high variability in genetic heterogeneity and phenotypic characteristics. The genetic etiology responsible for HCM in many individuals remains unclear. Many causative genes have already been identified, including β-tropomyosin or myosin heavy chain7(MYH7gene), cardiac myosin binding protein C (MYBPC3gene), cardiac troponin T type2(TNNT2gene), cardiac troponin I type3(TNNI3gene), myosin light chain3(MYL3gene), myosin light chain2regulatory (MYL2gene), cardiac a-actin (ACTC gene) and, titin (TTN gene) and etc.
Sanger sequencing is the traditional gold standard in the molecule diagnosis of genetic disease, but time-consuming, laborious and expensive to each investigate for the known candidate genes, especially in HCM. Next generation sequencing technology, with features of high through put, rapid sequencing and low cost, brings revolutionary changes in the fields of detecting gene mutations. The process of using this method to dectect mutations is simple. Researchers can combine whole genomere sequencing, target sequencing and transcriptome sequencing to dectect mutations in all-around, high accurate way.
Objective
Our aims are to identify the disease-causing gene mutation with familial hypertrophic cardiomyopathy (FHCM) by next generation sequencing, and to analyze the correlation between their genotype and phenotype, prognosis.
Methods
We choose two Chinese pedigrees with HCM and extracted their DNA from whole blood. According to each of the21established HCM genes, the exons in the functional regions of the genes with mutation were amplified with PCR by targeted next-generation DNA sequencing. Proband were sequenced with the next generation DNA sequencing method. According to the results of sequencing, the probands were followed by Sanger sequencing, and the exon in the functional regions of the gene were amplified with PCR and the products were sequenced for their family members. The relation between the genotype and phenotype was analyzed in these families, and the products were directly sequenced.100normal subjects were recruited as control.
Results
One missence mutation c.1987G>A (Arg663Cys) was identified in exon18of the beta myosin heavy chain gene in one family hypertrophic cardiomyopathy by next generation sequencing. Screening for of her family members by Sanger sequencing, and there are4family members also with mutation Arg663Cys in Exon18of the beta myosin heavy chain gene. The results of genetic test were normal in one hundred controls. The patients with mutation Arg663Cys clinically showed chest pain early, syncope, or sudden cardiac death. After undergoing Morrow operation, the proband had recovered well, and in the follow-up period for two years, she never feels chest pain and syncope.
A novel frame shift mutation c.1374delC (p.R458Rfs) was identified in exon14of the cardiac myosin binding protein C gene in pedigree2. Screening for of her family members by Sanger sequencing, and there are3family members also with mutation R458Rfs in Exon14of MYBPC3gene. The results of genetic test were normal in one hundred controls. However, the members of the same HCM family with the R458Rfs mutation showed differences in phenotype and prognosis.
Conclusions
The mutation Arg663Cys in Exon18of beta myosin heavy chain gene is the disease-causing gene in family1by next generation sequencing. The symptoms of patients occur early associated with left ventricular outflow tract obstruction and show chest pain, syncope and sudden death. Their prognosis seems poor in this pedigree of HCM. However, Morrow operation treatment can relieve symptoms and improve prognosis if the patients can actively carry out surgery.
A novel frame shift mutation c.1374delC (p.R458Rfs) was identified in exon14of the cardiac myosin binding protein C gene in pedigree2. The patients with this mutation clinically showed differences in phenotype and prognosis. The heterogeneity suggested that multiple factors may be involved in the pathogenesis of HCM.
Objective:
We aimed to retrospectively analyze the clinical features and prognosis of Hypertrophic cardiomyopathy patients with left ventricular thrombus.
Methods:
We retrospectively analyzed the data of HCM patients with left ventricular thrombus diagnosed by CMR in FuWai Hospital from January2002to December2012, and followed-up their survival states.
Results:
Left ventricular thrombosis was confirmed by MRI in6cases of HCM (thrombosis group), and no left ventricular thrombosis in284cases of HCM (no thrombus group), the ratio of family history of thrombosis group, ventricular arrhythmia, left atrial diameter, left ventricular diameter and ventricular aneurysm were significantly higher than those without thrombosis group (p<0.05), and left ventricular ejection fraction and outflow tract obstruction was significantly lower than no thrombus group (p<0.05).All patients received anticoagulation therapy with warfarin. During follow up (17-59) months, no thromboembolic events was recorded, and thrombus disappear in2patients.3cases died of heart failure and SCD. One patient received heart transplantation.
Conclusion:
Left ventricular thrombosis was seen in Hypertrophic cardiomyopathy patients with left ventricular aneurysm and lower left ventricular ejection fraction. Ventricular arrhythmia and poor prognosis were found in the majority of patients. Although embolic events occurred because of the left ventricular thrombus, warfarin can cure them.
Background:
Duchenne's or Becker's muscular dystrophy is a serious X-linked neuromuscular disorder. Mutations in the dystrophin gene on chromosome Xp21.1. have been reported to cause BMD. It primarily involved the skeletal muscle, characterized by weakness and muscle atrophy of hereditary muscle disease following as low progressive increase of symmetry. DMD is usually with serious condition and with a poor prognosis. BMD patients can usually walk and have a near normal life span, and there is a chance of them developing cardiac problems.
Objective:
To study the clinical characteristics and genetic analysis and management of Becker's muscular dystrophy combined with cardiac involvement, and to expand our understanding of this disorder.
Methods:
The proband and the family members had genetic testing, and these subjects also had physical examination and received muscle biopsy and routine pathological checks and cardiac evaluation. One hundred control subjects without diagnostic features of BMD were also recruited. Genomic DNA was extracted from leukocytes of peripheral blood from the patients and the control subjects. We screened the dystrophin gene in the indexes, and also screened for the mutation in their families and100controls.
Results:
The proband was diagnosed with BMD by the identification of a mutation (c.4998_5000Del GCA, p.1667delAla) in the exon35of the dystrophin gene. Three cases were diagnosed with BMD by the identification of this mutation. All genetically affected subjects had a history of weakness of the quadriceps femoris as well as increased serum creatine kinase level at rest and cardiac involvement. After heart transplantation, the proband recovered well.
Conclusion:
Genetic analysis enables a precise diagnosis of BMD, and heart transplantation is an effective treatment for the patient with severe heart failure.
引文
[1]MaronBJ, ShiraniJ, PoliacLC, et al. Sudden death in young competitive athletes: Clinical, demographic, and pathological profiles[J]. JAMA,1996.276(3):199-204.
[2]HershbergerRE, CowanJ, Morales A, et al. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy[J]. Circ Heart Fail,2009,2(3): 253-261.
[3]MaronBJ, TowbinJA, ThieneG, et al. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Councilon Clinical Cardiology, Heart Failure and Trans-plantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Inter disciplinary Working Groups; and Coun cilon Epidemiology and Prevention[J]. Circulation,2006,113(14):1807-1816.
[4]ROBERTR, ULRICHS. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy [J]. Circulation,2005,112:293-296.
[5]KonnoT, ChangS, SeidmanJG, et al. Genetics of hypertrophic cardiomyopathy[J]. Curt Opin Cardiol,2010,25(3):205-209.
[6]MoritaH, RehmHL, MenessesA, et al. Shared genetic causes of cardiac hypertrophy in children and adults[J]. N Engl J Med,2008,358(18):1899-1908.
[7]HoCY. Hypertrophic cardiomyopathy in 2012[J]. Circulation,2012,125(11): 1432-1438.
[8]Spencer DH, Tyagi M, Vallania F, et al. Performance of common analysis methods for detecting low-frequency single nucleotide variants in targetednext-generation sequence data[J]. J Mol Diagn,2014,16(l):75-88.
[9]AlcalaiR, SeidmanJG, SeidmanCE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics[J]. J Cardio vasc Electr,2008,19(1):104-110.
[10]SeidmanCE,SeidmanJG. Molecular genetic studies of familial hypertrophic cardiomyopathy[J]. Basic Res Cardiol,1998,93(Suppl.31:13-16.
[11]Jacnicke T, Diederich KW, Haas W, etal. The complete sequence of the human beta-myosinheavychain gene and an analysis of its product[J]. Genomics,1990,8: 194-206.
[12]Marian AJ. Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy[J]. Circulation,1995,92:1336-1347.
[13]Epstein ND, Fananapazir L, Lin HJ, et al. Evidence of genetic heterogeneity in five kindreds with familial hypertrophic cardiomyopathy[J]. Circulation,1992,85: 635-637.
[14]Solomon SD, Jareho JA, McKenna W, et al. Familial ypearophic cardiomyopathy is a genetically heterogeneous disease[J]. J Clin Invest,1990,86:993-999.
[15]Schwartz, Beckmann, Dufour C, etal. Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families[J]. Circ Res,1992,71:3-8.
[16]BaymentI, HoldenHM, SeLlersJR, et al. Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy[J]. Proc Nail Acad Sci USA,1995,92(9):3864-3868.
[7]R. Walsh, C. Rutland, R. Thomas, et al. Cardiomyopathy:a systematic review of disease-causing mutations in myosin heavy chain 7 and their phenotypic manifestations [J].Cardiology,2009,115 (1):49-60.
[18]WatkinsH, ThierfelderL, HwangDS, et al. Sporadic hypertrophic cardiomyopathy due to denovo myosin mutations[J]. J Clin Invest,1992,90:1666-1671.
[19]MornerS, Richard P, Kazzam E, et al. Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden [J]. J Mol Cell Cardiol,2003,35: 841-849.
[20]XIE Wen-li, LIU Wen-ling, HUDa-yi, et al. Mutation in beta myosin heavy chain gene: two mutations in Chinese with familial hypertrophic cardiomyopathy and the correlation between the genotype and phenotype [J]. Zhonghua Yi Xue Za Zhi, 2004,84(19):1610-1613.
[21]Marsiqia JD,Credidio FL, de Oliveira TG,,et al. Screening of MYH7, MYBPC3, and TNNT2 genes in Brazilian patients with hypertrophic cardiomyopathy [J]. Am Heart J,2013,166(4):775-782.
[22]宋雷,徐荣,吴格茹,等.肌球蛋白重链基因 Arg663Cys和Arg663His 突变 基因型与家族性肥厚型心肌病表型关系研究[J],中华心血管病杂志,2002, 30(3):131-135.
[23]Sara L.Van Driest,Michele A.Jaeger,Steve R.Ommen,et al.Comprehensive analysis of the Beta-Myosin Heavy Chain gene in 389 unrelated patients with Hypertrophic Cardiomyopathy[J]. J Am Coll Cardiol,2004,44(3):602-670.
[24]TakayukiN, AkiyoshiO, OkayamaH et al. A 985 polymorphism of the endothelin-2-gene and atrial fibrillationin patients with hypertrophic cardiomyopathy[J]. Circ J,2007,71:1932-1936.
[25]OlivottoI, CecchiF, CaseySA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy[J]. Circulation,2001,104:2517-2524.
[26]OzcanO, MustasaS, AhmetD. P-wave duration as a predictor for atrial fibrillation development in patients with hypertrophic cardiomyopathy [J]. Int J Cardiol,2003, 94:163-166.
[27]CecchiF, MontereggiHF, Olivottol, et al. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signala veraged P wave duration[J]. Heart, 1997,78:44-49.
[28]宋月洁,韩智红.肥厚型心肌病与心房颤动[J].心肺血管病杂志,2012,31(6)：765-767.
[29]SciagraR, SotgiaB, Olivottol, et al. Relation between atrial fibrillation and blunted hyperermic myocardial bloodflow in patients with hypertrophic cardiomyopathy[J]. Nulear Cardiology,2005,16:92-96.
[30]Schlossarek S, Mearini G, Carrier L. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy:mechanisms and therapeutic opportunities [J]. J Mol Cell Cardiol.2011,50(4):613-20.
[31]NiimuraH, BachinskiLL, SangwatanarojS, et al. Mutations in the gene for cardiao myosin binding protein and late-onset familial hypertrophic cardiomyopathy[J]. N Engl J Med,1998,338(18):1248-1257.
[32]Maron BN, Nichols PF, Pickle LW, et al. Patterns of inheritance in hypertrophic cardiomyopathy:assessment by M-mode and two-dimensional echoc ardiography[J]. AmJCardiol,1984,53(8):1087-1094.
[33]Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin binding protein gene mutations[J]. J Am Coll Cardiol,2001,38(2):315-321.
[34]Lin J, Zheng DD, Tao Q, et al.Two novel mutations of the MYBPC3 gene identified in Chinese families with hypertrophic cardiomyopathy. Can J Cardiol.2010,26(10):518-22.
[35]周帆,林标扬.第二代测序在检测人类基因突变中的应用.生命科学研究,2012,16(5)：452-455.
[1]Gersh BJ, MaronBJ, BonowRO, et al.2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J]. Circulation,2011.124(24): 2761-2796.
[2]MaronBJ, ShiraniJ, PoliacLC, et al. Sudden death in young competitive athletes: Clinical, demographic, and pathological profiles[J]. JAMA,1996.276(3):199-204.
[3]HershbergerRE, CowanJ, MoralesA, et al. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy[J]. Circ Heart Fail,2009,2(3):253-261.
[4]MaronBJ, TowbinJA, ThieneG, et al. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Councilon Clinical Cardiology, Heart Failure and Trans-plantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Inter disciplinary Working Groups; and Coun cilon Epidemiology and Prevention[J]. Circulation,2006,113(14):1807-1816.
[5]ROBERTR, ULRICHS. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy [J]. Circulation,2005,112:293-296.
[6]M.S. Maron.Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy [J].J Cardiovasc Magn Reson,2012,14:13.
[7]M.S. Maron, B.J. Maron, C. Harrigan et al.Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance[J].J Am Coll Cardiol, 2009,54:220-228.
[8]Mavrogeni S, Petrou E, Kolovou G, et al. Prediction of ventricular arrhythmias using cardiovascular magnetic resonance [J]. Eur Heart J Cardiovasc Imaging,2013, 14(6):518-525.
[9]Domenicucci S,Chiarella F,Bellotti P,et al.Long-term prospective assessment of left ventricular thrombus in anterior wall acute myocardial infarction and implications for a rational approach to embolic risk[J]. Am J Cardiol,1999,83(4):519-514.
[10]Dec GW, Fuster V. Idiopathic dilated cardiomyopath[J]. N Engl J Med,1994, 331(23):1564-1575.
[11]Guttmann OP, Rahman MS, O'Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review [J]. Heart,2013 Sep 7. doi:10.1136/heartjnl-2013-304276.
[12]Gradaus R, Lentschig M, Wichter T.Atypical hypertrophic cardiomyopathy with calcified, left ventricular apical thrombosis [J]. Z Kardiol,1999,88(4):290-295.
[13]Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study, Coronary Artery Risk Development in (Young) Adults[J]. Circulation,1995,92:785-789.
[14]Gersh BJ, Maron BJ, Bonow RO, et al.2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2011, 58:2703-2738.
[15]Kahya Eren N, Emren SV, Duygu H, Kocabas U. Left ventricular thrombus formation in a patient with normal ejection fraction [J]. Turk Kardiyol Dern Ars,2013,41(7):625-628.
[16]Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy [J]. Circulation,2008,118(15):1541-1549.
[17]Maron MS. Contrast-enhanced CMR in HCM: what lies behind the bright light of LGE and why it now matters [J]. JACC Cardiovasc Imaging,2013,6(5):597-599.
[18]Maron MS, Finley JJ, Bos JM,et al. Prevalence, clinical significance,and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy [J]. Circulation,2008,118:1541-1549.
[19]Toda G, Iliev II, Kawahara F, et al. Left ventricular aneurysm without coronary artery disease, incidence and clinical features:clinical analysis of 11 cases [J]. Intern Med,2000,39(7):531-536.
[20]Efthimiadis GK, Pliakos C, Pagourelias ED, et al. Hypertrophic cardiomyopathy with midventricular obstruction and aneurysm formation in a single family:case report [J].Cardiovascular Ultrasound,2009,7:26.
[21]Kalaria VG, Passannante MR, Shan T, et al. Effect of mitral regurgitation on left ventricular thrombus in dilated cardiomyopathy[J]. Am Heart J,1998,135(2ptl): 215-220.
[22]Falk RH, Foster E, Coats MH. Venmcular thrombi and thromboembolism in dilated cardiomyopathy:a prospective follow-up study[J].Am Heart J,1992,123:136-142.
[23]Monserrat L, Elliott PM, Gimeno JR,et al.Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy:an independent marker of sudden death risk in young patients[J].J Am Coll Cardiol,2003,42:873-879.
[24]Robertr, Ulrich S, Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy [J].Circulation,2005,112:293-296.
[25]夏淑东、吴必锋、金建美、陈君柱。特发性扩张型心肌病合并左心室室壁瘤形成的临床分析[J].中华心血管病杂志,2009(4)：314-319。
[26]Piva e Mattos B, Torres MA, Freitas VC,et al. Ventricular arrhythmias and left ventricular hypertrophy in hypertrophic cardiomyopathy [J]. Arq Bras Cardiol, 2013,100 (5):452-459.
[27]Maramattom BV, Yousef SR, Joseph G. Aortic saddle embolism and paraplegia due to a large left ventricular thrombus [J]. Ann Indian Acad Neurol,2013,16 (3):402-403.
[28]Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2002,39 (2):301-307.
[29]Murakami M,Takaki A,Nishida M,et al. Chronic stage left ventricular aneruysm and thrombus after myocardial infarction[J]. Blood Coagul Fibrinolysis,2006,17(6): 489-490.
[30]Kaku B.Intra-cardiac thrombus resolution after anti-coagulation therapy with dabigatran in a patient with mid-ventricularobstructive hypertrophic cardiomyopathy: a case report [J]. J Med Case Rep,2013,7(1):238
[1]Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2:implementation of multidisciplinary care. Lancet Neurol, 2010,9:177-189.
[2]Connuck DM, Sleeper LA, Colan SD, et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J,2008, 155:998-1005.
[3]Aartsma-Rus A, Van Deutekom JC, Fokkema IF,et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve,2006, 34:135-144.
[4]Takeshima Y, Yagi M, Okizuka Y, et al.Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet,2010,55:379-388.
[5]Kaspar RW, Allen HD, Ray WC, et al. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. Circ Cardiovasc Genet,2009,2:544-551.
[6]Fayssoil A, Nardi O, Orlikowski D, et al.Cardiomyopathy in Duchenne muscular dystrophy:pathogenesis and therapeutics. Heart Fail Rev,2010,15(1):103-107.
[7]Lapidos KA, Kakkar R, McNally EM.The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res,2004,94(8):1023-1031.
[8]Rybakova IN, Patel JR, Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol,2000,150(5):1209-1214.
[9]Judge DP, Kass DA, Thompson WR, et al. Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. Am J Cardiovasc Drugs, 2011,11:287-294.
[10]TW Prior, SJ Bridgeman.Experience and strategy for the molecular testing of Duchenne muscular dystrophy J Mol Diagn,2005,7:317-326.
[11]T Lalic, RH Vossen, J Coffa, et al.Deletion and duplication screening in the DMD gene using MLPA.Eur J Hum Genet,2005,13:1231-1234.
[12]KM Flanigan, A von Niederhausern, DM Dunn, et al.Rapid direct sequence analysis of the dystrophin gene.Am J Hum Genet,2003,72:931-939.
[13]KM Dent, DM Dunn, AC von Niederhausern, et al.Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort.Am J Med Genet A, 2005,134:295-298.
[14]Lovitt S, Moore SL, Marden FA. The use of MRI in the evaluation of myopathy. Clin Neurophysiol,2006,117:486-495.
[15]Lovitt S, Marden FA, Gundogdu B, et al. MRI in myopathy. Neurol Clin,2004,22: 529-533.
[16]Hor KN, Taylor MD, Al-Khalidi HR, et al. Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy:effect of age and left ventricular systolic function. J Cardiovasc Magn Reson,2013,15(1):107.
[17]Muntoni F, Cau M, Ganau A, et al. Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med,1993,329:921-925.
[18]Romfh A, McNally EM.Cardiac assessment in duchenne and becker muscular dystrophies. Curr Heart Fail Rep,2010,7(4):212-218.
[19]De Palma C, Morisi F, Cheli S, et al. Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis,2012,15(3):e418.
[20]Hoffman EP, Reeves E, Damsker J, et al. Novel approaches to corticosteroid treatment in duchenne muscular dystrophy. Phys Med Rehabil Clin N Am,2012, 23:821-828.
[21]Miyagoe-Suzuki Y, Takeda S.Gene therapy for muscle disease. Exp Cell Res,2010, 316:3087-3092.
[22]Nakamura A, Takeda S. Exon-skipping therapy for Duchenne muscular dystrophy. Neuropathology,2009,29:494-501.
[23]Malik V, Rodino-Klapac LR, Viollet L, et al. Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy. Ther Adv Neurol Disord,2010,3:379-389.
[24]Rodino-Klapac LR, Mendell JR, Sahenk Z. Update on the treatment of Duchenne muscular dystrophy. Curr Neurol Neurosci Rep,2013,13(3):332.
[25]Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol,2005,45(6):855-857.
[26]Packer M, Coats AJ, Fowler MB,et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med,2001,344(22):1651-1658.
[27]H. Kajimoto, K. Ishigaki, K. Okumura et al.Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy.Circ J,2006,70:991-999.
[28]Chamberlain JS. ACE inhibitor bulks up muscle. Nat Med,2007,13:125-126.
[29]Bader H, Garrigue S, Lafitte S, et al. Intra-left ventricular electromechanical asynchrony. A new independent predictor of severe cardiac events in heart failure patients. J Am Coll Cardiol,2004,43(2):248-256.
[30]Sampaolesi M, Torrente Y, Innocenzi A, et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science,2003,301 (5632):487-492.
[31]Wu RS, Gupta S, Brown RN,et al. Clinical outcomes after cardiac transplantation in muscular dystrophy patients.J Heart Lung Transplant,2010, 29(4):432-438.
[32]F. Patane, E. Zingarelli, M. Attisani, et al.Successful heart transplantation in Becker's muscular dystrophy.Eur J Cardiothorac Surg,2006,29:250
[1]Gersh BJ, MaronBJ, BonowRO, et al.2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J]. Circulation,2011,124(24): 2761-2796.
[2]BrockR. Functional obstruction of the left ventriele(acquired aortic subvalvular stenosis) [J]. Guys Hosp Rep,1957,106(4):221-238.
[3]TeareD. Asymmetrical hypertrophy of the heart in young adults[J]. Br Heart, 1958,20(1):1-8.
[4]Braunwald E, Lambert CT, Rockoff SD, et al. Idiopathic hypertrophic subaortic stenosis, I:a description of the disease based upon an analysis of 64 patients [J]. Circulation,1964,30(suppl4):119.
[5]MaronBJ, ShiraniJ, PoliacLC, et al. Sudden death in young competitive athletes: Clinical, demographic, and pathological profiles [J]. JAMA,1996,276(3): 199-204.
[6]HershbergerRE, CowanJ, MoralesA, et al. Progress with genetic cardiomyopathies:screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy[J]. Circ Heart Fail,2009,2(3):253-261.
[7]MaronBJ, TowbinJA, ThieneG, et al. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Councilon Clinical Cardiology, Heart Failure and Trans-plantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Inter disciplinary Working Groups; and Coun cilon Epidemiology and Prevention[J]. Circulation,2006, 113(14):1807-1816.
[8]ROBERTR, ULRICHS. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy [J]. Circulation,2005,112:293-296.
[9]CarassoS, YangH, WooA, etal. Diastolic myocardial mechanics in hypertrophic cardiomyopathy[J]. J Am Soc Echocardiogr,2010,23(2):164-171.
[10]M.S. Maron, I. Olivotto, S. Betocchi et al.Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy [J].N Engl J Med,2003,348:295-303.
[11]S. Joshi, U.K. Patel, S.S. Yao et al. Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity [J].J Am Soc Echocardiogr,2011,24:75-82.
[12]Argulian E, Chaudhry FA. Stress testing in patients with hypertrophic cardiomyopathy [J]. Prog Cardiovasc Dis,2012,54(6):477-482.
[13]Schlossarek S, Schuermann F, Geertz B, et al. Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice [J]. J Muscle Res Cell Motil,2012,33(1):5-15.
[14]Sequeira V, Wijnker PJ, Nijenkamp LL, et al. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations [J]. Circ Res,2013,112 (11):1491-1505.
[15]Koga Y, Miyazaki Y, Shida M, et al. Increased cardiovascular responses to norepinephrine in patients with hypertrophic cardiomyopathy [J]. Jpn Heart J,1990,31(3):271-285.
[16]Elmas E, Doesch C, Fluechter S, et al. Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy [J]. Int J Cardiovasc Imaging,2011,27(4):547-556.
[17]Coats CJ, Gallagher MJ, Foley M, et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy [J]. Eur Heart J,2013,34(32):2529-2537.
[18]Fernandes F, Arteaga-Fernandez E,Antunes Mde O, et al. Plasma pro-B-type natriuretic peptide testing as a screening method for hypertrophic cardiomyopathy[J]. J Card Fail,2012,18(7):564-568.
[19]Geisterfer LowranceAAT, KassS, et al. Amolecular basis for familial hypertrophic cardiomyopathy:aβ cardiacmyosin heavy chain gene missense mutation[J]. Cell,1990,62(5):999-1006.
[20]AlcalaiR, SeidmanJG, SeidmanCE. Genetic basis of hypertrophic cardiomyopathy:from bench to the clinics[J]. J Cardio vasc Electr,2008,19(1): 104-110.
[21]Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2009,54:201-211.
[22]KonnoT, ChangS, SeidmanJG, et al. Genetics of hypertrophic cardiomyopathy[J]. Curt Opin Cardiol,2010,25(3):205-209.
[23]MoritaH, RehmHL, MenessesA, et al. Shared genetic causes of cardiac hypertrophy in children and adults[J]. N Engl J Med,2008,358(18):1899-1908.
[24]HoCY. Hypertrophic cardiomyopathy in 2012[J]. Circulation,2012,125(11): 1432-1438.
[25]SeidmanCE, SeidmanJG. Molecular genetic studies of familial hypertrophic cardiomyopathy[J]. Basic Res Cardiol,1998,93(31):13-16.
[26]BaymentI, HoldenHM, SeLlersJR, et al. Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy[J]. Proc Nail Acad Sci USA,1995,92(9): 3864-3868.
[27]EnjutoM, FrancinoA, NavarroL, et al. Malignant hypertrophic cardiomyopathy caused by the Arg723Gly mutation inBeta-myosin heavy chain gene[J]. J Mol Cell Cardiol,2000,32(12):2307-2313.
[28]郑冬冬,杨俊华,董宁征,等.中国汉族家族性肥厚型心肌病人群MYH7基因Arg723Gly突变分析[J].中华心血管病杂志,2006,34(3)：208-211.
[29]WatkinsH, RosenzweigA, HwangDS, et al. Characteristics and prognostic implications of myosin missense mutations infamilial hypertrophic cardiomyopathy[J]. N EngI J Med,1992,326(17):1108-1114.
[30]宋雷,徐荣,吴格茹,等.肌球蛋白重链基因Arg663Cys和Arg663His突变基因型与家族性肥厚型心肌病表型关系研究[J].中华心血管病杂志,2002,30(3)：131-135.
[31]邹玉宝,王继征,武鹏翥,等.β肌球蛋白重链基因Ala26Val突变中国人肥厚型心肌病热点突变[J].中华心血管病杂志,2002,30(8)：473-476.
[32]LiuSX, HuSJ, SunJ, etal. Characteristics of the beta myosin heavy chain gene Ala26Val mutation in a Chinese family with hypertrophic cardiomyopathy[J]. Eur J Intern Med,2005,16(5):328-333.
[33]NiimuraH, BachinskiLL, SangwatanarojS, et al. Mutations in the gene for cardiao myosin binding protein and late-onset familial hypertrophic cardiomyopathy[J]. N Engl J Med,1998,338(18):1248-1257.
[34]Maron BN, Nichols PF, Pickle LW, et al. Patterns of inheritance in hypertrophic cardiomyopathy:assessment by M-mode and two-dimensional echoc ardiography[J]. AmJCardiol,1984,53(8):1087-1094.
[35]Oakley CE, Chamoun J, Brown LJ, et al. Myosin binding proteinC:Enigmatic regulator of cardiac contraction[J]. Int J Biochem Cell Biol,2007,39(12): 2161-2166.
[36]Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin binding protein gene mutations[J]. J Am Coll Cardiol,2001,38(2):315-321.
[37]Michels M, Hoedemaekers YM, KoffiardMJ, etal. Familial screening and genetic counseling in hypertrophic cardiomyopathy:the Rotterdam experience[J]. Neth Heart J,2007,15(5):184-189.
[38]ThierfelderL, WatkinsH, MacraeC, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy:a disease of the sareomere[J]. Cell,1994,77(5):701-712.
[39]SeidmanCE, SeidmanJG. Molecular genetic studies of familial hypertrophic cardiomyopathy[J]. Basic Res Cardiol,1998,93(Suppl3):13-16.
[40]WatkinsH, MckennaWJ, ThierfelderL, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy[J]. N Engl J Med,1995,332(16):1058-1064.
[41]AnanR, ShonoH, KisanukiA, et al. Patients with familial hypertrophic cardiomyopathy caused by a Phel10Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis[J]. Circulation,1998,98:391-397.
[42]RichardP, CharronP, CarrierL, et al. Hypertrophic cardiomyopathy:distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy[J]. Circulation,2003,107(17):2227-2232.
[43]HayashiT, ArimuraT, ItohS, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy[J]. J Am Coff Cardiol,2004, 44(11):2192-2201.
[44]OsioA, TanLL, ChenSN, et al. Myozenin2 is a novel gene for human hypertrophic cardiomyopathy [J]. Circ Res,2007,100(6):766-768.
[45]SatohM, TakahashiM, SakamotoT, et al. Structur alanalysis of the titin gene in hypertrophic cardiomyopathy:identification of a novel disease gene[J]. Biochem Biophys Res Commun,1999,262(2):1411-1417.
[46]GeierC, PerrotA, ozcelikC, et al. Mutations in the human muscle LI M protein gene in families with hypertrophic cardiomyopathy[J]. Circulation,2003, 107(10):1390-1395.
[47]VasileVC, OmmenSR, EdwardsWD, et al. A missense mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to hypertrophic cardiomyopathy[J]. Biochem Biophys Res Commun,2006,345(3):998-1003.
[48]MayrJA, MerkelO, KohlweinSD, etal. Mitochondrial phosphate carrier deficiency:a novel disorder of oxidative phosphorylation[J]. Am J Hum Genet, 2007,80(3):478-484.
[49]Ingles J, Doolan A, Chiu C, et al. Compound and double mutations in patients with hypertrophic cardiomyopathy:implications for genetic testing and counseling[J]. J Med Genet,2005,42:e59.
[50]Girolami F, Ho CY, Semsarian C, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations [J]. J Am Coll Cardiol,2010,55:1444-1453.
[51]KelIy M, Semsarian C. Multiple mutations in genetic cardiovascular disease: a marker of disease severity[J]?Circ Cardiovasc Genet,2009,2(2):182-190.
[52]MaronBJ. Hypertrophiccardiomyopathy:a systematic review[J]. JAMA,2002, 287(10):1308-1320.
[53]Yin WH, Chen YH, Wei J, et al. Associations between endothelin-1 and adiponectin in chronic heart failure [J]. Cardiology,2011,118(4):207-216.
[54]Wess G, Schinner C, Weber K, et al.Association of A31P and A74T polymorphisms in the myosin binding protein C3 gene and hypertrophic cardiomyopathy in Maine Coon and other breed cats[J]. J Vet Intern Med,2010, 24(3):527-532.
[55]Penicka M, Gregor P, Krupicka J, et al.Tumour necrosis factor-alpha soluble receptors type I are related to symptoms and left ventricular function in hypertrophic cardiomyopathy [J]. Can J Cardiol,2001,17(7):777-784.
[56]Carstens N, van der Merwe L, Revera M, et al. Genetic variation in angiotensin Ⅱ type 2 receptor gene influences extent of left ventricular hypertrophy in hypertrophic cardiomyopathy independent of blood pressure [J]. J Renin Angiotensin Aldosterone Syst,2011,12(3):274-280.
[57]Patel R, Lim DS, Reddy D, et al. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy [J]. J Mol Cell Cardiol,2000,32(12):2369-2377.
[58]Theopistou A, Anastasakis A, Miliou A, etal. Clinical features of hypertrophic Cardiomyopathy caused by an Arg278Cys missense mutation in the cardiac troponin T gene[J]. Am J Cardiol,2004,94(2):246-249.
[59]Consevage MW, Salada GC, Baylen BG, et al. A new missense mutation, Arg719Gln, in the beta-cardiac heavy chain myosin gene of patients with familial hypertrophic cardiomyopathy [J]. Hum Mol Genet,1994,3(6): 1025-1026.
[60]宋艳瑞,刘忠,顾淑莲,等.肥厚型心肌病的致病分子机制研究进展[J].遗传,2011,33(6)：549-557.
[61]LimDS, LutucutaS, BachireddyP, et al. AngioteusinII blockade reverses myocardial fibrosis in a trans genic mouse model of human hypertrophic cardiomyopathy[J]. Circulmion,2001,103(6):789-791.
[62]Brito D, Madeira H. Malignant mutations in hypertrophic cardiomyopathy: fact or fancy?[J]. Rev Port Cardiol,2005,24(9):1137-1146.
[63]Friedrich FW, Wilding BR, Reischmann S, et al. Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy [J]. Hum Mol Genet,2012,21(14):3237-3254.
[64]Ommen SR. Hypertrophic Cardiomyopathy[J]. Curr Probl Cardiol,2011,36(11): 409-453.
[65]M.S. Maron.Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy [J].J Cardiovasc Magn Reson,2012,14:13.
[66]Guarise A, Faccioli N, Foti G, et al.Role of echocardiography and cardiac MRI in depicting morphological and functional imaging findings useful for diagnosing hypertrophic cardiomyopathy[J]. Radiol Med,2011,16(2):197-210.
[67]M.S. Maron, B.J. Maron, C. Harrigan et al.Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance [J].J Am Coll Cardiol,2009,54:220-228.
[68]Mavrogeni S, Petrou E, Kolovou G, et al. Prediction of ventricular arrhythmias using cardiovascular magnetic resonance[J]. Eur Heart J Cardiovasc Imaging,2013,14(6):518-525.
[69]郭航远主编.新编心肌病学[M].第1版.浙江：浙江大学出版社,2007,195-208.
[70]葛均波,崔洁.无创检查在肥厚型心肌病诊断中的应用[J].国际心血管病杂志,2011,38(1)：5-8.
[71]Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction [J]. Circulation,2006,114:2232-2239.
[72]CarassoS, YangH, WooA, et al. Diastolic myocardial mechanics in hypertrophic cardiomyopathy[J]. J Am Soc Echoeardiogr,2010,23(2):164-171.
[73]Maron MS, Finley JJ, Bos JM,et al. Prevalence, clinical significance,and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy[J]. Circulation,2008,118:1541-1549.
[74]Sorajja P, Ommen SR, Nishimura RA, et al. Myocardial bridging inadult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol,2003, 42:889-894.
[75]OlivottoI, CecchiF, CaseySA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy [J]. Circulation,2001,104(21): 2517-2524.
[76]Maron BJ, Spirito P, Shen WK, et al. Prevention of sudden cardiac death and selection of patients for implantable cardioverter defibrillators in hypertrophic cardiomyopathy[J]. JAMA,2007,298(4):405-412.
[77]Ostman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence strategies to prevent sudden death [J]. Fundam Clin Pharmacol,2010, 24(5):637-652.
[78]Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2005,45(8):1251-1258.
[79]BauersachsJ, StorkS, KungM, et al. HMGCoA reductase inhibitionand left ventricular mass in hypertrophic cardiomyopathy:a randomized placebo controlled pilot study [J]. Eur J Clin Invest,2007,37:852-829
[80]YamazakiT, Suzuki J, Shimamoto R, et al. A new therapeutic strategy for hypertrophic nonobstructive cardionwopathy in humans:A randomized and prospective study with an angiotensin II receptor blocker[J]. Int Heart J,2007, 48:715-724.
[81]Araujo AQ,Arteaga E,lanni BM,et al. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy [J].Am J Cardiol,2005,96(11):1563-1567.
[82]Kawano H, Toda G, Nakamizo R, et al. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy [J]. Circ J,2005, 69(10):1244-1248.
[83]LombardiR, RodriguezG, ChensN, et al. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dsfunction in a transgenic rabbit model of human cardiomyopathy throughthiol sensitive mechanisms [J].Circulation,2009,119:1398-1407.
[84]Hamada M, Aono J, Ikeda S, et al. Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy:its relationship to transmitral Doppler flow profiles [J]. Circ J,2007,71(10):1540-1544.
[85]Stauffer BL, Konhilas JP, Luczak ED, et al. Soy diet worsens heart disease in mice [J]. J Clin Invest,2006,116(1):209-216.
[86]Tsybouleva N, Zhang L, Chen S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy [J]. Circulation,2004, 109(10):1284-1291.
[87]LechinM, QuifionesMA, OmranA, et al. Angiotensin-I converting enzyme genotypes and left ventrieular hypertrophy in patients with hypertrophic cardiomyopathy[J]. Circulation,1995,92(7):1808-1812.
[88]ZhaoQS, BeckAJ, VitaleJM, et al. Injection of wild type embryonic stem cells into Mstl trans genic blastocysts prevents adult onset cardiomyopathy[J]. StemC Rev,2011,7(2):326-330.
[89]FosslienE. Mitochondrial medicine-cardiomyopathy caused by defective oxidative phosphorylation[J]. Ann Clin Lab Sci,2003,33(4):371-395.
[90]rinz C, Farr M, Hering D, et al. The Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J]. Dtsch Arztebl Int,2011,108(13):209-215.
[91]MARON BJ. Is septal ablation preferable to surgicalmyomectomy for obstructive hypertrophic cardiomyopathy[J].Circulation,2007.116:196-206.
[92]Callans DJ. Ablation of atrial fibrillation in the setting of hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol,2008,19:1015-1016.
[93]Di Donna P, Olivotto I, Delcre SD, et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace,2010,12:347-355.
[94]Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2003,42:1687-1713.
[2]HershbergerRE, CowanJ, Morales A, et al. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy[J]. Circ Heart Fail,2009,2(3): 253-261.
[3]MaronBJ, TowbinJA, ThieneG, et al. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Councilon Clinical Cardiology, Heart Failure and Trans-plantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Inter disciplinary Working Groups; and Coun cilon Epidemiology and Prevention[J]. Circulation,2006,113(14):1807-1816.
[4]ROBERTR, ULRICHS. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy [J]. Circulation,2005,112:293-296.
[5]KonnoT, ChangS, SeidmanJG, et al. Genetics of hypertrophic cardiomyopathy[J]. Curt Opin Cardiol,2010,25(3):205-209.
[6]MoritaH, RehmHL, MenessesA, et al. Shared genetic causes of cardiac hypertrophy in children and adults[J]. N Engl J Med,2008,358(18):1899-1908.
[7]HoCY. Hypertrophic cardiomyopathy in 2012[J]. Circulation,2012,125(11): 1432-1438.
[8]Spencer DH, Tyagi M, Vallania F, et al. Performance of common analysis methods for detecting low-frequency single nucleotide variants in targetednext-generation sequence data[J]. J Mol Diagn,2014,16(l):75-88.
[9]AlcalaiR, SeidmanJG, SeidmanCE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics[J]. J Cardio vasc Electr,2008,19(1):104-110.
[10]SeidmanCE,SeidmanJG. Molecular genetic studies of familial hypertrophic cardiomyopathy[J]. Basic Res Cardiol,1998,93(Suppl.31:13-16.
[11]Jacnicke T, Diederich KW, Haas W, etal. The complete sequence of the human beta-myosinheavychain gene and an analysis of its product[J]. Genomics,1990,8: 194-206.
[12]Marian AJ. Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy[J]. Circulation,1995,92:1336-1347.
[13]Epstein ND, Fananapazir L, Lin HJ, et al. Evidence of genetic heterogeneity in five kindreds with familial hypertrophic cardiomyopathy[J]. Circulation,1992,85: 635-637.
[14]Solomon SD, Jareho JA, McKenna W, et al. Familial ypearophic cardiomyopathy is a genetically heterogeneous disease[J]. J Clin Invest,1990,86:993-999.
[15]Schwartz, Beckmann, Dufour C, etal. Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families[J]. Circ Res,1992,71:3-8.
[16]BaymentI, HoldenHM, SeLlersJR, et al. Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy[J]. Proc Nail Acad Sci USA,1995,92(9):3864-3868.
[7]R. Walsh, C. Rutland, R. Thomas, et al. Cardiomyopathy:a systematic review of disease-causing mutations in myosin heavy chain 7 and their phenotypic manifestations [J].Cardiology,2009,115 (1):49-60.
[18]WatkinsH, ThierfelderL, HwangDS, et al. Sporadic hypertrophic cardiomyopathy due to denovo myosin mutations[J]. J Clin Invest,1992,90:1666-1671.
[19]MornerS, Richard P, Kazzam E, et al. Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden [J]. J Mol Cell Cardiol,2003,35: 841-849.
[20]XIE Wen-li, LIU Wen-ling, HUDa-yi, et al. Mutation in beta myosin heavy chain gene: two mutations in Chinese with familial hypertrophic cardiomyopathy and the correlation between the genotype and phenotype [J]. Zhonghua Yi Xue Za Zhi, 2004,84(19):1610-1613.
[21]Marsiqia JD,Credidio FL, de Oliveira TG,,et al. Screening of MYH7, MYBPC3, and TNNT2 genes in Brazilian patients with hypertrophic cardiomyopathy [J]. Am Heart J,2013,166(4):775-782.
[22]宋雷,徐荣,吴格茹,等.肌球蛋白重链基因 Arg663Cys和Arg663His 突变 基因型与家族性肥厚型心肌病表型关系研究[J],中华心血管病杂志,2002, 30(3):131-135.
[23]Sara L.Van Driest,Michele A.Jaeger,Steve R.Ommen,et al.Comprehensive analysis of the Beta-Myosin Heavy Chain gene in 389 unrelated patients with Hypertrophic Cardiomyopathy[J]. J Am Coll Cardiol,2004,44(3):602-670.
[24]TakayukiN, AkiyoshiO, OkayamaH et al. A 985 polymorphism of the endothelin-2-gene and atrial fibrillationin patients with hypertrophic cardiomyopathy[J]. Circ J,2007,71:1932-1936.
[25]OlivottoI, CecchiF, CaseySA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy[J]. Circulation,2001,104:2517-2524.
[26]OzcanO, MustasaS, AhmetD. P-wave duration as a predictor for atrial fibrillation development in patients with hypertrophic cardiomyopathy [J]. Int J Cardiol,2003, 94:163-166.
[27]CecchiF, MontereggiHF, Olivottol, et al. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signala veraged P wave duration[J]. Heart, 1997,78:44-49.
[28]宋月洁,韩智红.肥厚型心肌病与心房颤动[J].心肺血管病杂志,2012,31(6)：765-767.
[29]SciagraR, SotgiaB, Olivottol, et al. Relation between atrial fibrillation and blunted hyperermic myocardial bloodflow in patients with hypertrophic cardiomyopathy[J]. Nulear Cardiology,2005,16:92-96.
[30]Schlossarek S, Mearini G, Carrier L. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy:mechanisms and therapeutic opportunities [J]. J Mol Cell Cardiol.2011,50(4):613-20.
[31]NiimuraH, BachinskiLL, SangwatanarojS, et al. Mutations in the gene for cardiao myosin binding protein and late-onset familial hypertrophic cardiomyopathy[J]. N Engl J Med,1998,338(18):1248-1257.
[32]Maron BN, Nichols PF, Pickle LW, et al. Patterns of inheritance in hypertrophic cardiomyopathy:assessment by M-mode and two-dimensional echoc ardiography[J]. AmJCardiol,1984,53(8):1087-1094.
[33]Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin binding protein gene mutations[J]. J Am Coll Cardiol,2001,38(2):315-321.
[34]Lin J, Zheng DD, Tao Q, et al.Two novel mutations of the MYBPC3 gene identified in Chinese families with hypertrophic cardiomyopathy. Can J Cardiol.2010,26(10):518-22.
[35]周帆,林标扬.第二代测序在检测人类基因突变中的应用.生命科学研究,2012,16(5)：452-455.
[1]Gersh BJ, MaronBJ, BonowRO, et al.2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J]. Circulation,2011.124(24): 2761-2796.
[2]MaronBJ, ShiraniJ, PoliacLC, et al. Sudden death in young competitive athletes: Clinical, demographic, and pathological profiles[J]. JAMA,1996.276(3):199-204.
[3]HershbergerRE, CowanJ, MoralesA, et al. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy[J]. Circ Heart Fail,2009,2(3):253-261.
[4]MaronBJ, TowbinJA, ThieneG, et al. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Councilon Clinical Cardiology, Heart Failure and Trans-plantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Inter disciplinary Working Groups; and Coun cilon Epidemiology and Prevention[J]. Circulation,2006,113(14):1807-1816.
[5]ROBERTR, ULRICHS. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy [J]. Circulation,2005,112:293-296.
[6]M.S. Maron.Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy [J].J Cardiovasc Magn Reson,2012,14:13.
[7]M.S. Maron, B.J. Maron, C. Harrigan et al.Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance[J].J Am Coll Cardiol, 2009,54:220-228.
[8]Mavrogeni S, Petrou E, Kolovou G, et al. Prediction of ventricular arrhythmias using cardiovascular magnetic resonance [J]. Eur Heart J Cardiovasc Imaging,2013, 14(6):518-525.
[9]Domenicucci S,Chiarella F,Bellotti P,et al.Long-term prospective assessment of left ventricular thrombus in anterior wall acute myocardial infarction and implications for a rational approach to embolic risk[J]. Am J Cardiol,1999,83(4):519-514.
[10]Dec GW, Fuster V. Idiopathic dilated cardiomyopath[J]. N Engl J Med,1994, 331(23):1564-1575.
[11]Guttmann OP, Rahman MS, O'Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review [J]. Heart,2013 Sep 7. doi:10.1136/heartjnl-2013-304276.
[12]Gradaus R, Lentschig M, Wichter T.Atypical hypertrophic cardiomyopathy with calcified, left ventricular apical thrombosis [J]. Z Kardiol,1999,88(4):290-295.
[13]Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study, Coronary Artery Risk Development in (Young) Adults[J]. Circulation,1995,92:785-789.
[14]Gersh BJ, Maron BJ, Bonow RO, et al.2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2011, 58:2703-2738.
[15]Kahya Eren N, Emren SV, Duygu H, Kocabas U. Left ventricular thrombus formation in a patient with normal ejection fraction [J]. Turk Kardiyol Dern Ars,2013,41(7):625-628.
[16]Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy [J]. Circulation,2008,118(15):1541-1549.
[17]Maron MS. Contrast-enhanced CMR in HCM: what lies behind the bright light of LGE and why it now matters [J]. JACC Cardiovasc Imaging,2013,6(5):597-599.
[18]Maron MS, Finley JJ, Bos JM,et al. Prevalence, clinical significance,and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy [J]. Circulation,2008,118:1541-1549.
[19]Toda G, Iliev II, Kawahara F, et al. Left ventricular aneurysm without coronary artery disease, incidence and clinical features:clinical analysis of 11 cases [J]. Intern Med,2000,39(7):531-536.
[20]Efthimiadis GK, Pliakos C, Pagourelias ED, et al. Hypertrophic cardiomyopathy with midventricular obstruction and aneurysm formation in a single family:case report [J].Cardiovascular Ultrasound,2009,7:26.
[21]Kalaria VG, Passannante MR, Shan T, et al. Effect of mitral regurgitation on left ventricular thrombus in dilated cardiomyopathy[J]. Am Heart J,1998,135(2ptl): 215-220.
[22]Falk RH, Foster E, Coats MH. Venmcular thrombi and thromboembolism in dilated cardiomyopathy:a prospective follow-up study[J].Am Heart J,1992,123:136-142.
[23]Monserrat L, Elliott PM, Gimeno JR,et al.Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy:an independent marker of sudden death risk in young patients[J].J Am Coll Cardiol,2003,42:873-879.
[24]Robertr, Ulrich S, Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy [J].Circulation,2005,112:293-296.
[25]夏淑东、吴必锋、金建美、陈君柱。特发性扩张型心肌病合并左心室室壁瘤形成的临床分析[J].中华心血管病杂志,2009(4)：314-319。
[26]Piva e Mattos B, Torres MA, Freitas VC,et al. Ventricular arrhythmias and left ventricular hypertrophy in hypertrophic cardiomyopathy [J]. Arq Bras Cardiol, 2013,100 (5):452-459.
[27]Maramattom BV, Yousef SR, Joseph G. Aortic saddle embolism and paraplegia due to a large left ventricular thrombus [J]. Ann Indian Acad Neurol,2013,16 (3):402-403.
[28]Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2002,39 (2):301-307.
[29]Murakami M,Takaki A,Nishida M,et al. Chronic stage left ventricular aneruysm and thrombus after myocardial infarction[J]. Blood Coagul Fibrinolysis,2006,17(6): 489-490.
[30]Kaku B.Intra-cardiac thrombus resolution after anti-coagulation therapy with dabigatran in a patient with mid-ventricularobstructive hypertrophic cardiomyopathy: a case report [J]. J Med Case Rep,2013,7(1):238
[1]Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2:implementation of multidisciplinary care. Lancet Neurol, 2010,9:177-189.
[2]Connuck DM, Sleeper LA, Colan SD, et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J,2008, 155:998-1005.
[3]Aartsma-Rus A, Van Deutekom JC, Fokkema IF,et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve,2006, 34:135-144.
[4]Takeshima Y, Yagi M, Okizuka Y, et al.Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet,2010,55:379-388.
[5]Kaspar RW, Allen HD, Ray WC, et al. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. Circ Cardiovasc Genet,2009,2:544-551.
[6]Fayssoil A, Nardi O, Orlikowski D, et al.Cardiomyopathy in Duchenne muscular dystrophy:pathogenesis and therapeutics. Heart Fail Rev,2010,15(1):103-107.
[7]Lapidos KA, Kakkar R, McNally EM.The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res,2004,94(8):1023-1031.
[8]Rybakova IN, Patel JR, Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol,2000,150(5):1209-1214.
[9]Judge DP, Kass DA, Thompson WR, et al. Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. Am J Cardiovasc Drugs, 2011,11:287-294.
[10]TW Prior, SJ Bridgeman.Experience and strategy for the molecular testing of Duchenne muscular dystrophy J Mol Diagn,2005,7:317-326.
[11]T Lalic, RH Vossen, J Coffa, et al.Deletion and duplication screening in the DMD gene using MLPA.Eur J Hum Genet,2005,13:1231-1234.
[12]KM Flanigan, A von Niederhausern, DM Dunn, et al.Rapid direct sequence analysis of the dystrophin gene.Am J Hum Genet,2003,72:931-939.
[13]KM Dent, DM Dunn, AC von Niederhausern, et al.Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort.Am J Med Genet A, 2005,134:295-298.
[14]Lovitt S, Moore SL, Marden FA. The use of MRI in the evaluation of myopathy. Clin Neurophysiol,2006,117:486-495.
[15]Lovitt S, Marden FA, Gundogdu B, et al. MRI in myopathy. Neurol Clin,2004,22: 529-533.
[16]Hor KN, Taylor MD, Al-Khalidi HR, et al. Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy:effect of age and left ventricular systolic function. J Cardiovasc Magn Reson,2013,15(1):107.
[17]Muntoni F, Cau M, Ganau A, et al. Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med,1993,329:921-925.
[18]Romfh A, McNally EM.Cardiac assessment in duchenne and becker muscular dystrophies. Curr Heart Fail Rep,2010,7(4):212-218.
[19]De Palma C, Morisi F, Cheli S, et al. Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis,2012,15(3):e418.
[20]Hoffman EP, Reeves E, Damsker J, et al. Novel approaches to corticosteroid treatment in duchenne muscular dystrophy. Phys Med Rehabil Clin N Am,2012, 23:821-828.
[21]Miyagoe-Suzuki Y, Takeda S.Gene therapy for muscle disease. Exp Cell Res,2010, 316:3087-3092.
[22]Nakamura A, Takeda S. Exon-skipping therapy for Duchenne muscular dystrophy. Neuropathology,2009,29:494-501.
[23]Malik V, Rodino-Klapac LR, Viollet L, et al. Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy. Ther Adv Neurol Disord,2010,3:379-389.
[24]Rodino-Klapac LR, Mendell JR, Sahenk Z. Update on the treatment of Duchenne muscular dystrophy. Curr Neurol Neurosci Rep,2013,13(3):332.
[25]Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol,2005,45(6):855-857.
[26]Packer M, Coats AJ, Fowler MB,et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med,2001,344(22):1651-1658.
[27]H. Kajimoto, K. Ishigaki, K. Okumura et al.Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy.Circ J,2006,70:991-999.
[28]Chamberlain JS. ACE inhibitor bulks up muscle. Nat Med,2007,13:125-126.
[29]Bader H, Garrigue S, Lafitte S, et al. Intra-left ventricular electromechanical asynchrony. A new independent predictor of severe cardiac events in heart failure patients. J Am Coll Cardiol,2004,43(2):248-256.
[30]Sampaolesi M, Torrente Y, Innocenzi A, et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science,2003,301 (5632):487-492.
[31]Wu RS, Gupta S, Brown RN,et al. Clinical outcomes after cardiac transplantation in muscular dystrophy patients.J Heart Lung Transplant,2010, 29(4):432-438.
[32]F. Patane, E. Zingarelli, M. Attisani, et al.Successful heart transplantation in Becker's muscular dystrophy.Eur J Cardiothorac Surg,2006,29:250
[1]Gersh BJ, MaronBJ, BonowRO, et al.2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J]. Circulation,2011,124(24): 2761-2796.
[2]BrockR. Functional obstruction of the left ventriele(acquired aortic subvalvular stenosis) [J]. Guys Hosp Rep,1957,106(4):221-238.
[3]TeareD. Asymmetrical hypertrophy of the heart in young adults[J]. Br Heart, 1958,20(1):1-8.
[4]Braunwald E, Lambert CT, Rockoff SD, et al. Idiopathic hypertrophic subaortic stenosis, I:a description of the disease based upon an analysis of 64 patients [J]. Circulation,1964,30(suppl4):119.
[5]MaronBJ, ShiraniJ, PoliacLC, et al. Sudden death in young competitive athletes: Clinical, demographic, and pathological profiles [J]. JAMA,1996,276(3): 199-204.
[6]HershbergerRE, CowanJ, MoralesA, et al. Progress with genetic cardiomyopathies:screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy[J]. Circ Heart Fail,2009,2(3):253-261.
[7]MaronBJ, TowbinJA, ThieneG, et al. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Councilon Clinical Cardiology, Heart Failure and Trans-plantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Inter disciplinary Working Groups; and Coun cilon Epidemiology and Prevention[J]. Circulation,2006, 113(14):1807-1816.
[8]ROBERTR, ULRICHS. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy [J]. Circulation,2005,112:293-296.
[9]CarassoS, YangH, WooA, etal. Diastolic myocardial mechanics in hypertrophic cardiomyopathy[J]. J Am Soc Echocardiogr,2010,23(2):164-171.
[10]M.S. Maron, I. Olivotto, S. Betocchi et al.Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy [J].N Engl J Med,2003,348:295-303.
[11]S. Joshi, U.K. Patel, S.S. Yao et al. Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity [J].J Am Soc Echocardiogr,2011,24:75-82.
[12]Argulian E, Chaudhry FA. Stress testing in patients with hypertrophic cardiomyopathy [J]. Prog Cardiovasc Dis,2012,54(6):477-482.
[13]Schlossarek S, Schuermann F, Geertz B, et al. Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice [J]. J Muscle Res Cell Motil,2012,33(1):5-15.
[14]Sequeira V, Wijnker PJ, Nijenkamp LL, et al. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations [J]. Circ Res,2013,112 (11):1491-1505.
[15]Koga Y, Miyazaki Y, Shida M, et al. Increased cardiovascular responses to norepinephrine in patients with hypertrophic cardiomyopathy [J]. Jpn Heart J,1990,31(3):271-285.
[16]Elmas E, Doesch C, Fluechter S, et al. Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy [J]. Int J Cardiovasc Imaging,2011,27(4):547-556.
[17]Coats CJ, Gallagher MJ, Foley M, et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy [J]. Eur Heart J,2013,34(32):2529-2537.
[18]Fernandes F, Arteaga-Fernandez E,Antunes Mde O, et al. Plasma pro-B-type natriuretic peptide testing as a screening method for hypertrophic cardiomyopathy[J]. J Card Fail,2012,18(7):564-568.
[19]Geisterfer LowranceAAT, KassS, et al. Amolecular basis for familial hypertrophic cardiomyopathy:aβ cardiacmyosin heavy chain gene missense mutation[J]. Cell,1990,62(5):999-1006.
[20]AlcalaiR, SeidmanJG, SeidmanCE. Genetic basis of hypertrophic cardiomyopathy:from bench to the clinics[J]. J Cardio vasc Electr,2008,19(1): 104-110.
[21]Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2009,54:201-211.
[22]KonnoT, ChangS, SeidmanJG, et al. Genetics of hypertrophic cardiomyopathy[J]. Curt Opin Cardiol,2010,25(3):205-209.
[23]MoritaH, RehmHL, MenessesA, et al. Shared genetic causes of cardiac hypertrophy in children and adults[J]. N Engl J Med,2008,358(18):1899-1908.
[24]HoCY. Hypertrophic cardiomyopathy in 2012[J]. Circulation,2012,125(11): 1432-1438.
[25]SeidmanCE, SeidmanJG. Molecular genetic studies of familial hypertrophic cardiomyopathy[J]. Basic Res Cardiol,1998,93(31):13-16.
[26]BaymentI, HoldenHM, SeLlersJR, et al. Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy[J]. Proc Nail Acad Sci USA,1995,92(9): 3864-3868.
[27]EnjutoM, FrancinoA, NavarroL, et al. Malignant hypertrophic cardiomyopathy caused by the Arg723Gly mutation inBeta-myosin heavy chain gene[J]. J Mol Cell Cardiol,2000,32(12):2307-2313.
[28]郑冬冬,杨俊华,董宁征,等.中国汉族家族性肥厚型心肌病人群MYH7基因Arg723Gly突变分析[J].中华心血管病杂志,2006,34(3)：208-211.
[29]WatkinsH, RosenzweigA, HwangDS, et al. Characteristics and prognostic implications of myosin missense mutations infamilial hypertrophic cardiomyopathy[J]. N EngI J Med,1992,326(17):1108-1114.
[30]宋雷,徐荣,吴格茹,等.肌球蛋白重链基因Arg663Cys和Arg663His突变基因型与家族性肥厚型心肌病表型关系研究[J].中华心血管病杂志,2002,30(3)：131-135.
[31]邹玉宝,王继征,武鹏翥,等.β肌球蛋白重链基因Ala26Val突变中国人肥厚型心肌病热点突变[J].中华心血管病杂志,2002,30(8)：473-476.
[32]LiuSX, HuSJ, SunJ, etal. Characteristics of the beta myosin heavy chain gene Ala26Val mutation in a Chinese family with hypertrophic cardiomyopathy[J]. Eur J Intern Med,2005,16(5):328-333.
[33]NiimuraH, BachinskiLL, SangwatanarojS, et al. Mutations in the gene for cardiao myosin binding protein and late-onset familial hypertrophic cardiomyopathy[J]. N Engl J Med,1998,338(18):1248-1257.
[34]Maron BN, Nichols PF, Pickle LW, et al. Patterns of inheritance in hypertrophic cardiomyopathy:assessment by M-mode and two-dimensional echoc ardiography[J]. AmJCardiol,1984,53(8):1087-1094.
[35]Oakley CE, Chamoun J, Brown LJ, et al. Myosin binding proteinC:Enigmatic regulator of cardiac contraction[J]. Int J Biochem Cell Biol,2007,39(12): 2161-2166.
[36]Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin binding protein gene mutations[J]. J Am Coll Cardiol,2001,38(2):315-321.
[37]Michels M, Hoedemaekers YM, KoffiardMJ, etal. Familial screening and genetic counseling in hypertrophic cardiomyopathy:the Rotterdam experience[J]. Neth Heart J,2007,15(5):184-189.
[38]ThierfelderL, WatkinsH, MacraeC, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy:a disease of the sareomere[J]. Cell,1994,77(5):701-712.
[39]SeidmanCE, SeidmanJG. Molecular genetic studies of familial hypertrophic cardiomyopathy[J]. Basic Res Cardiol,1998,93(Suppl3):13-16.
[40]WatkinsH, MckennaWJ, ThierfelderL, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy[J]. N Engl J Med,1995,332(16):1058-1064.
[41]AnanR, ShonoH, KisanukiA, et al. Patients with familial hypertrophic cardiomyopathy caused by a Phel10Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis[J]. Circulation,1998,98:391-397.
[42]RichardP, CharronP, CarrierL, et al. Hypertrophic cardiomyopathy:distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy[J]. Circulation,2003,107(17):2227-2232.
[43]HayashiT, ArimuraT, ItohS, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy[J]. J Am Coff Cardiol,2004, 44(11):2192-2201.
[44]OsioA, TanLL, ChenSN, et al. Myozenin2 is a novel gene for human hypertrophic cardiomyopathy [J]. Circ Res,2007,100(6):766-768.
[45]SatohM, TakahashiM, SakamotoT, et al. Structur alanalysis of the titin gene in hypertrophic cardiomyopathy:identification of a novel disease gene[J]. Biochem Biophys Res Commun,1999,262(2):1411-1417.
[46]GeierC, PerrotA, ozcelikC, et al. Mutations in the human muscle LI M protein gene in families with hypertrophic cardiomyopathy[J]. Circulation,2003, 107(10):1390-1395.
[47]VasileVC, OmmenSR, EdwardsWD, et al. A missense mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to hypertrophic cardiomyopathy[J]. Biochem Biophys Res Commun,2006,345(3):998-1003.
[48]MayrJA, MerkelO, KohlweinSD, etal. Mitochondrial phosphate carrier deficiency:a novel disorder of oxidative phosphorylation[J]. Am J Hum Genet, 2007,80(3):478-484.
[49]Ingles J, Doolan A, Chiu C, et al. Compound and double mutations in patients with hypertrophic cardiomyopathy:implications for genetic testing and counseling[J]. J Med Genet,2005,42:e59.
[50]Girolami F, Ho CY, Semsarian C, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations [J]. J Am Coll Cardiol,2010,55:1444-1453.
[51]KelIy M, Semsarian C. Multiple mutations in genetic cardiovascular disease: a marker of disease severity[J]?Circ Cardiovasc Genet,2009,2(2):182-190.
[52]MaronBJ. Hypertrophiccardiomyopathy:a systematic review[J]. JAMA,2002, 287(10):1308-1320.
[53]Yin WH, Chen YH, Wei J, et al. Associations between endothelin-1 and adiponectin in chronic heart failure [J]. Cardiology,2011,118(4):207-216.
[54]Wess G, Schinner C, Weber K, et al.Association of A31P and A74T polymorphisms in the myosin binding protein C3 gene and hypertrophic cardiomyopathy in Maine Coon and other breed cats[J]. J Vet Intern Med,2010, 24(3):527-532.
[55]Penicka M, Gregor P, Krupicka J, et al.Tumour necrosis factor-alpha soluble receptors type I are related to symptoms and left ventricular function in hypertrophic cardiomyopathy [J]. Can J Cardiol,2001,17(7):777-784.
[56]Carstens N, van der Merwe L, Revera M, et al. Genetic variation in angiotensin Ⅱ type 2 receptor gene influences extent of left ventricular hypertrophy in hypertrophic cardiomyopathy independent of blood pressure [J]. J Renin Angiotensin Aldosterone Syst,2011,12(3):274-280.
[57]Patel R, Lim DS, Reddy D, et al. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy [J]. J Mol Cell Cardiol,2000,32(12):2369-2377.
[58]Theopistou A, Anastasakis A, Miliou A, etal. Clinical features of hypertrophic Cardiomyopathy caused by an Arg278Cys missense mutation in the cardiac troponin T gene[J]. Am J Cardiol,2004,94(2):246-249.
[59]Consevage MW, Salada GC, Baylen BG, et al. A new missense mutation, Arg719Gln, in the beta-cardiac heavy chain myosin gene of patients with familial hypertrophic cardiomyopathy [J]. Hum Mol Genet,1994,3(6): 1025-1026.
[60]宋艳瑞,刘忠,顾淑莲,等.肥厚型心肌病的致病分子机制研究进展[J].遗传,2011,33(6)：549-557.
[61]LimDS, LutucutaS, BachireddyP, et al. AngioteusinII blockade reverses myocardial fibrosis in a trans genic mouse model of human hypertrophic cardiomyopathy[J]. Circulmion,2001,103(6):789-791.
[62]Brito D, Madeira H. Malignant mutations in hypertrophic cardiomyopathy: fact or fancy?[J]. Rev Port Cardiol,2005,24(9):1137-1146.
[63]Friedrich FW, Wilding BR, Reischmann S, et al. Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy [J]. Hum Mol Genet,2012,21(14):3237-3254.
[64]Ommen SR. Hypertrophic Cardiomyopathy[J]. Curr Probl Cardiol,2011,36(11): 409-453.
[65]M.S. Maron.Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy [J].J Cardiovasc Magn Reson,2012,14:13.
[66]Guarise A, Faccioli N, Foti G, et al.Role of echocardiography and cardiac MRI in depicting morphological and functional imaging findings useful for diagnosing hypertrophic cardiomyopathy[J]. Radiol Med,2011,16(2):197-210.
[67]M.S. Maron, B.J. Maron, C. Harrigan et al.Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance [J].J Am Coll Cardiol,2009,54:220-228.
[68]Mavrogeni S, Petrou E, Kolovou G, et al. Prediction of ventricular arrhythmias using cardiovascular magnetic resonance[J]. Eur Heart J Cardiovasc Imaging,2013,14(6):518-525.
[69]郭航远主编.新编心肌病学[M].第1版.浙江：浙江大学出版社,2007,195-208.
[70]葛均波,崔洁.无创检查在肥厚型心肌病诊断中的应用[J].国际心血管病杂志,2011,38(1)：5-8.
[71]Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction [J]. Circulation,2006,114:2232-2239.
[72]CarassoS, YangH, WooA, et al. Diastolic myocardial mechanics in hypertrophic cardiomyopathy[J]. J Am Soc Echoeardiogr,2010,23(2):164-171.
[73]Maron MS, Finley JJ, Bos JM,et al. Prevalence, clinical significance,and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy[J]. Circulation,2008,118:1541-1549.
[74]Sorajja P, Ommen SR, Nishimura RA, et al. Myocardial bridging inadult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol,2003, 42:889-894.
[75]OlivottoI, CecchiF, CaseySA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy [J]. Circulation,2001,104(21): 2517-2524.
[76]Maron BJ, Spirito P, Shen WK, et al. Prevention of sudden cardiac death and selection of patients for implantable cardioverter defibrillators in hypertrophic cardiomyopathy[J]. JAMA,2007,298(4):405-412.
[77]Ostman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence strategies to prevent sudden death [J]. Fundam Clin Pharmacol,2010, 24(5):637-652.
[78]Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2005,45(8):1251-1258.
[79]BauersachsJ, StorkS, KungM, et al. HMGCoA reductase inhibitionand left ventricular mass in hypertrophic cardiomyopathy:a randomized placebo controlled pilot study [J]. Eur J Clin Invest,2007,37:852-829
[80]YamazakiT, Suzuki J, Shimamoto R, et al. A new therapeutic strategy for hypertrophic nonobstructive cardionwopathy in humans:A randomized and prospective study with an angiotensin II receptor blocker[J]. Int Heart J,2007, 48:715-724.
[81]Araujo AQ,Arteaga E,lanni BM,et al. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy [J].Am J Cardiol,2005,96(11):1563-1567.
[82]Kawano H, Toda G, Nakamizo R, et al. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy [J]. Circ J,2005, 69(10):1244-1248.
[83]LombardiR, RodriguezG, ChensN, et al. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dsfunction in a transgenic rabbit model of human cardiomyopathy throughthiol sensitive mechanisms [J].Circulation,2009,119:1398-1407.
[84]Hamada M, Aono J, Ikeda S, et al. Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy:its relationship to transmitral Doppler flow profiles [J]. Circ J,2007,71(10):1540-1544.
[85]Stauffer BL, Konhilas JP, Luczak ED, et al. Soy diet worsens heart disease in mice [J]. J Clin Invest,2006,116(1):209-216.
[86]Tsybouleva N, Zhang L, Chen S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy [J]. Circulation,2004, 109(10):1284-1291.
[87]LechinM, QuifionesMA, OmranA, et al. Angiotensin-I converting enzyme genotypes and left ventrieular hypertrophy in patients with hypertrophic cardiomyopathy[J]. Circulation,1995,92(7):1808-1812.
[88]ZhaoQS, BeckAJ, VitaleJM, et al. Injection of wild type embryonic stem cells into Mstl trans genic blastocysts prevents adult onset cardiomyopathy[J]. StemC Rev,2011,7(2):326-330.
[89]FosslienE. Mitochondrial medicine-cardiomyopathy caused by defective oxidative phosphorylation[J]. Ann Clin Lab Sci,2003,33(4):371-395.
[90]rinz C, Farr M, Hering D, et al. The Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J]. Dtsch Arztebl Int,2011,108(13):209-215.
[91]MARON BJ. Is septal ablation preferable to surgicalmyomectomy for obstructive hypertrophic cardiomyopathy[J].Circulation,2007.116:196-206.
[92]Callans DJ. Ablation of atrial fibrillation in the setting of hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol,2008,19:1015-1016.
[93]Di Donna P, Olivotto I, Delcre SD, et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace,2010,12:347-355.
[94]Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2003,42:1687-1713.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |